about
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesCDK4/6 inhibition in luminal breast cancerTherapeutic strategies targeting cancer stem cellsRoscovitine in cancer and other diseasesTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsComparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype SelectivityDevelopment of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent KinasesCyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of BromodomainsA kinase-independent function of CDK6 links the cell cycle to tumor angiogenesisMolecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug designOlomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1)Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitroA high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage responseData integration to prioritize drugs using genomics and curated data.Long non-coding RNA LUCAT1 is associated with poor prognosis in human non-small lung cancer and regulates cell proliferation via epigenetically repressing p21 and p57 expressionCDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.The molecular balancing act of p16(INK4a) in cancer and aging.Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression.Studies on quantitative phosphopeptide analysis by matrix-assisted laser desorption/ionization mass spectrometry without label, chromatography or calibration curvesMulticellular tumor spheroid models to explore cell cycle checkpoints in 3D.A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.Discovery of novel 5-fluoro-N(2),N(4)-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9.Tampering with cell division by using small-molecule inhibitors of CDK-CKS protein interactions.The Role of CDK4/6 Inhibition in Breast Cancer.Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanomaInsights on Structural Characteristics and Ligand Binding Mechanisms of CDK2Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.High Skp2/Low p57(Kip2) Expression is Associated with Poor Prognosis in Human Breast Carcinoma.Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignanciesCritical reanalysis of the methods that discriminate the activity of CDK2 from CDK1Conditional gene deletion with DiCre demonstrates an essential role for CRK3 in Leishmania mexicana cell cycle regulation.Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.Interferon regulatory factor 4 sustains CD8(+) T cell expansion and effector differentiation.The C/EBPδ protein is stabilized by estrogen receptor α activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer.Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.Cell cycle-related kinase in carcinogenesisCyclin-dependent kinase inhibitors closer to market launch?Dinaciclib for the treatment of breast cancer.Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.
P2860
Q21245492-CF96E7EC-4050-422B-8F6C-2048088F7E35Q26739836-CB4A899F-DC14-40B4-862A-923130C41E80Q26781398-F936C5D7-AAF4-4150-8ECE-FB5A3DD1EEE4Q26799874-E393EA92-8D4E-462A-A89B-F17E7E35CD68Q26827580-91424C28-C935-485C-80D0-3C1B22BE1A41Q27675539-B451D410-E94E-4C66-A83E-A68CDE4F6A27Q27677453-B51C0BE8-3B01-4655-9B89-82984835F7A1Q27679876-48C831CC-A82A-43DD-BEFC-90D7B69BAF32Q28296641-CA691C96-2A5A-4BE7-99AF-C89371F854BFQ28533443-A026F799-B557-4032-8963-E4117EB5EF1CQ28534229-825DE9D5-8FEC-47A4-AA1E-C44FCD716DD9Q28537944-8644120A-F8D6-4D3F-A087-5E12707C1946Q28539430-6C1E6961-06BA-43F5-BED0-ACE52E9EE695Q31102946-F53CA866-2480-4465-921E-C838740DB38AQ33709689-052F08D3-1CC2-4E7F-9FF2-64A9DA08CB43Q33864755-B26D2951-E20F-4909-9BA4-BB919F88847CQ34038585-431CAED3-2CD9-4364-93CE-9F083832F9E2Q34060715-1AED250E-3D57-4430-B312-7BF2DF40E3C4Q34477921-8BF66547-A550-4F6F-918A-82597BCAF260Q34581413-C052BF3A-713B-444F-8B3F-396B145F0D60Q34687067-0C8E611A-8469-4198-B0F3-827FC2D8D5ECQ35524888-755199CF-17EE-4686-8157-AB8D1CB958F5Q35548864-5A913A5D-624D-4DD5-AB80-3C108DFCA824Q35586728-046F0B29-AD06-434A-BE15-29EB976A1CFBQ35706499-CA97B27F-B9EA-4889-9A90-A08670EF9F5BQ35722786-499F13A5-01C2-4355-A2A2-994CEE96FD3BQ35846538-DBA80526-E559-4526-A9F0-92194E0BDAE6Q35918810-0594B4FE-1D85-487A-87D5-17FD474E18DDQ36020882-82C2FD2E-D677-467C-840F-941750CE42D1Q36780688-C4EC0498-BF34-4B61-91EC-65F8356F0BE0Q36956909-AC9FB2CE-078C-4E08-BB4A-1909648AE6D9Q37020701-1DAF460A-D03B-4273-9BDB-6417B50CAF67Q37199802-FD29597E-DEB0-4EEA-B292-E84875E52AF5Q37374912-568EFD0B-4DF4-4402-9282-0017539A8B61Q37418549-894F895C-5A4A-48F7-B10B-7C0B3B6AF91EQ37716446-4B64E717-6A0B-4018-876F-9778E5743142Q38064457-BAD9CE78-2761-4328-974E-63034C7BC096Q38100203-8B43DCFA-DA25-4F6F-879A-F5C14D58418CQ38238282-349B5A1B-79C7-4B00-BD23-8E964A481FE0Q38248633-4D84175B-1F58-4F6A-847E-AB295980CC46
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The CDK inhibitors in cancer research and therapy.
@en
The CDK inhibitors in cancer research and therapy.
@nl
type
label
The CDK inhibitors in cancer research and therapy.
@en
The CDK inhibitors in cancer research and therapy.
@nl
prefLabel
The CDK inhibitors in cancer research and therapy.
@en
The CDK inhibitors in cancer research and therapy.
@nl
P2860
P1476
The CDK inhibitors in cancer research and therapy
@en
P2093
Jonas Cicenas
P2860
P2888
P304
P356
10.1007/S00432-011-1039-4
P577
2011-08-30T00:00:00Z